NGM Bio is a clinical-stage biopharmaceutical company with a drug discovery approach that is currently focused on key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. NGM has a portfolio of seven product candidates, five of which are in clinical testing. NGM's most advanced and wholly-owned product candidate, NGM282, is an engineered variant of the human hormone FGF19 for the treatment of non-alcoholic steatohepatitis (NASH). In February 2015, the Company entered into a five-year research collaboration, product development and license agreement with Merck